We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In more bad news for AstraZeneca, the European Medicines Agency (EMA) announced that its safety committee is investigating reports of capillary leak syndrome, a rare, potentially life-threatening disorder, in individuals inoculated with the company’s COVID-19 vaccine. Read More
Emergent BioSolutions’ beleaguered Baltimore, Md., facility, which Johnson & Johnson has taken over to exclusively produce its vaccine, may be cleared to start shipping out J&J doses before the month is over, according to the White House’s COVID-19 response leader. Read More
The Biden administration has sent a budget proposal to Congress, outlining its spending priorities for fiscal year 2022, but it sheds almost no light on the president’s plans to fund FDA initiatives. Read More
Biogen and Chinese drugmaker Bio-Thera Solutions have teamed to develop a biosimilar of Roche’s Actemra (tocilizumab), BAT1806, currently being evaluated in phase 3 trials for moderate-to-severe rheumatoid arthritis. Read More
The FDA has approved a new, biweekly dosing regimen for ImClone’s cancer drug, Erbitux (cetuximab), for patients with a certain form of EGFR-expressing colorectal cancer or head and neck squamous-cell carcinoma. Read More
The FDA has granted full approval for Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) for treating women with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior lines of therapy. Read More
The FDA has released minutes from its meetings in early 2021 with industry on PDUFA reauthorization, discussions that focused on the agency’s Sentinel drug surveillance system and proposed Risk Evaluation and Mitigation Strategies (REMS) assessments. Read More
Eli Lilly’s and Incyte’s Janus kinase (JAK) inhibitor Olumiant (baricitinib) proved unable to significantly reduce progression to noninvasive ventilation for COVID-19 patients in a phase 3 trial, though the drug still managed to significantly reduce the risk of death. Read More